公开(公告)号：US5391569A

公开(公告)日：1995-02-21

申请号：US127804

申请日：1993-09-28

申请人： Jean-Daniel Brion ,  Guillaume Le Baut ,  Guillaume Poissonnet ,  Lucy De Montarby ,  Larbi Belachmi ,  Jacqueline Bonnet ,  Massimo Sabatini ,  Charles Tordjman

发明人： Jean-Daniel Brion ,  Guillaume Le Baut ,  Guillaume Poissonnet ,  Lucy De Montarby ,  Larbi Belachmi ,  Jacqueline Bonnet ,  Massimo Sabatini ,  Charles Tordjman

IPC分类号： A61K31/35 ,  A61K31/352 ,  A61K31/66 ,  A61P3/00 ,  A61P19/10 ,  A61P29/00 ,  A61P43/00 ,  C07D311/12 ,  C07D311/14 ,  C07D311/16 ,  C07D311/18 ,  C07D311/58 ,  C07D311/64 ,  C07D311/70 ,  C07D311/72 ,  C07D405/04 ,  C07D409/04 ,  C07F9/655 ,  A61K31/40 ,  A61K31/445 ,  A61K31/47

CPC分类号： C07D405/04 ,  C07D311/58 ,  C07D311/64 ,  C07D311/70 ,  C07D409/04

摘要： A compound selected from those of formula (I): ##STR1## in which the groups R.sub.1 to R.sub.8 are as defined the description. Medicaments.

摘要翻译： 选自式（I）的化合物：其中基团R1至R8如说明书所定义。 药剂

公开(公告)号：US06350757B1

公开(公告)日：2002-02-26

申请号：US09621742

申请日：2000-07-21

申请人： Solo Goldstein ,  Guillaume Poissonnet ,  Jean-Gilles Parmentier ,  Jean-Daniel Brion ,  Mark Millan ,  Anne Dekeyne ,  Jean Boutin

发明人： Solo Goldstein ,  Guillaume Poissonnet ,  Jean-Gilles Parmentier ,  Jean-Daniel Brion ,  Mark Millan ,  Anne Dekeyne ,  Jean Boutin

IPC分类号： C07D47114

CPC分类号： C07D471/04

摘要： A compound selected from those of formula (I): wherein: represents single or double bond, R1 represents hydrogen, alkyl, —R6-aryl, —R6-cycloalkyl, —R6-heterocycle, —CO2R7—, —COR8, or —CONHR8, wherein R6, R7, and R8 are as defined in the description, R2 represents cyano, mono- or di-alkylaminoalkylaminocarbonyl, —CO2R8, —CONHR8, —NR8R9, —NHCO2R7, or —COR8 wherein R7, R8, and R9 are as defined in the description, R3 and R4 together form (C3-C10)cycloalkyl, R5 represents hydrogen, alkyl, or arylalkyl, Ra, Rb, Rc, Rd, which may be identical or different, represent a group as defined in the description, its isomers, and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same which are useful in the treatment of CNS disorders.

摘要翻译： 选自式（I）的化合物：其中：CUSTOM-CHARACTER FILE =“US06350757-20020226-P00900.TIF”ID =“CUSTOM-CHARACTER-00001”>表示单键或双键，R1表示氢，烷基， -R6-芳基，-R6-环烷基，-R6-杂环，-CO2R7-，-COR8或-CONHR8，其中R6，R7和R8如说明书中所定义，R 2表示氰基，单或二烷基氨基烷基氨基羰基 ，-CO 2 R 8，-CONHR 8，-NR 8 R 9，-NHCO 2 R 7或-COR 8，其中R 7，R 8和R 9如说明书中所定义，R 3和R 4一起形成（C 3 -C 10）环烷基，R 5表示氢，烷基或芳烷基 可以相同或不同的R a，R b，R c，R d表示本说明书中定义的基团，其异构体及其药学上可接受的酸或碱加成盐，以及含有该基团的药物，其可用于 治疗中枢神经系统疾病。

公开(公告)号：US5877190A

公开(公告)日：1999-03-02

申请号：US943562

申请日：1997-10-03

申请人： Alain Dhainaut ,  Guillaume Poissonnet ,  Emmanuel Canft ,  Michel Lonchampt

发明人： Alain Dhainaut ,  Guillaume Poissonnet ,  Emmanuel Canft ,  Michel Lonchampt

IPC分类号： C07D233/64 ,  A61K31/05 ,  A61K31/11 ,  A61K31/135 ,  A61K31/15 ,  A61K31/165 ,  A61K31/275 ,  A61K31/34 ,  A61K31/343 ,  A61K31/38 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/47 ,  A61K31/495 ,  A61P11/00 ,  A61P11/08 ,  A61P25/00 ,  A61P27/16 ,  A61P29/00 ,  A61P37/00 ,  A61P37/08 ,  A61P43/00 ,  C07C43/20 ,  C07C45/71 ,  C07C47/546 ,  C07C47/57 ,  C07C47/575 ,  C07C49/798 ,  C07C49/84 ,  C07C49/86 ,  C07C65/21 ,  C07C67/14 ,  C07C69/157 ,  C07C69/24 ,  C07C69/28 ,  C07C69/75 ,  C07C201/12 ,  C07C205/20 ,  C07C205/44 ,  C07C205/60 ,  C07C217/82 ,  C07C235/44 ,  C07C235/60 ,  C07C251/48 ,  C07C251/54 ,  C07C251/86 ,  C07C255/53 ,  C07C255/54 ,  C07C255/58 ,  C07C257/18 ,  C07C259/10 ,  C07C323/31 ,  C07D209/08 ,  C07D213/06 ,  C07D213/50 ,  C07D215/12 ,  C07D231/12 ,  C07D307/79 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/06 ,  C07D401/02

CPC分类号： C07D307/79 ,  C07C205/20 ,  C07C205/44 ,  C07C205/60 ,  C07C235/60 ,  C07C251/48 ,  C07C251/86 ,  C07C255/53 ,  C07C259/10 ,  C07C45/71 ,  C07C47/57 ,  C07C47/575 ,  C07D209/08 ,  C07D213/50 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/06

摘要： A compound of formula (I): ##STR1## wherein: R.sub.1 represents unsubstituted or substituted cycloalkyl, phenyl, naphthyl, heterocyclic, alkyl or alkenyl,A represents a bond, oxygen, sulphur, a group ##STR2## a group ##STR3## or a group ##STR4## wherein Rc represents hydrogen, alkyl or cycloalkyl, R.sub.2 represents halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, cycloalkyl, formyl, carboxy, alkylcarbonyl, cycloalkylcarbonyl, alkoxycarbonyl, cycloalkyloxycarbonyl, optionally substituted carbamoyl, optionally substituted amino, formylamino, cyano, optionally substituted amidino, hydroxyaminomethyl, amide oxime, hydrazono, or a group selected from: ##STR5## wherein R.sub.21, R.sub.22 and R.sub.23 are as defined in the description, R.sub.3 represents hydrogen or alkyl, cycloalkyl or acyl,or ##STR6## together form the ring ##STR7## X is oxygen, sulphur, or NR", B is phenyl, Ra and Rb, which may be identical or different, each represents hydrogen, halogen, or alkyl, hydroxy, alkoxy, carboxy, polyhalogenoalkyl, cyano, nitro, alkoxycarbonyl, cycloalkyloxycarbonyl, amino, carbamoyl, sulfo, alkylsulfonyl, cycloalkylsulfonyl or aminosulfonyl, their isomers, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same which are useful as PDE IV inhibitors.

摘要翻译： 式（I）化合物：其中：R 1表示未取代或取代的环烷基，苯基，萘基，杂环基，烷基或烯基，A表示键，氧，硫， 取代或未取代的烷基，取代或未取代的链烯基，取代或未取代的炔基，环烷基，甲酰基，羧基，烷基羰基，环烷基羰基，烷氧基羰基，环烷氧基羰基， 任选取代的氨基甲酰基，任选取代的氨基，甲酰氨基，氰基，任选取代的脒基，羟基氨基甲基，酰胺肟，亚氨基或选自以下的基团：其中R 21，R 22和R 23如说明书中所定义，R 3表示氢或烷基 ，环烷基或酰基，或一起形成环，X是氧，硫或NR“，B是苯基，R a和R b可以相同或不同，各自表示氢， 卤素或烷基，羟基，烷氧基，羧基，多卤代烷基，氰基，硝基，烷氧基羰基，环烷氧基羰基，氨基，氨基甲酰基，磺基，烷基磺酰基，环烷基磺酰基或氨基磺酰基，它们的异构体及其与药学上可接受的酸或碱的加成盐， 含有该药物的药物可用作PDE IV抑制剂。

公开(公告)号：US06992085B2

公开(公告)日：2006-01-31

申请号：US10195019

申请日：2002-07-12

申请人： Solo Goldstein ,  Guillaume Poissonnet ,  Jean-Gilles Parmentier ,  Pierre Lestage ,  Brian Lockhart

发明人： Solo Goldstein ,  Guillaume Poissonnet ,  Jean-Gilles Parmentier ,  Pierre Lestage ,  Brian Lockhart

IPC分类号： A61K31/4985 ,  C07D471/04

CPC分类号： C07D471/04

摘要： A compound selected from those of formula (I): wherein: Ra represents linear or branched (C1–C6)alkylene, X represents a group selected from W1, —C(W1)—W2—, —W2—C(W1)—, —W2—C(W1)W2—, —W2—Ra— and —CH(OR1)— wherein W1, W2 and R1 are as defined in the description, when Y represents aryl or heteroaryl, or X represents a group selected from single bond, —C(W1)—, —W2—C(W1)—, —W2—Ra and —CH(OR1)— wherein W1, W2, Ra and R1 are as defined hereinbefore, when Y represents a fused bicyclic group, of formula: wherein: A represents nitrogen-containing heterocycle having from 4 to 7 ring members that is unsaturated or partially saturated and optionally contains a second hetero atom, B represents phenyl ring optionally substituted by one or more groups as defined in the description, its isomers, and addition salts thereof with a pharmaceutically acceptable acid or base, medicinal products containing the same are useful in the treatment of cognitive deficiencies.

摘要翻译： 选自式（I）的化合物：其中：R a表示直链或支链（C 1 -C 6 -C 6）亚烷基，X表示选自W SUB -C（W 1） - W 2 - ， - W 2 -C（W 1） ） - ，-W 2 -C（W 1）W 2 - ， - W 2